Garbage In, Garbage Out: The Case for More Accurate Process Modeling in Manufacturing Economics - A case study in capturing indirect costs and benefits. - BioPharm International

ADVERTISEMENT

Garbage In, Garbage Out: The Case for More Accurate Process Modeling in Manufacturing Economics
A case study in capturing indirect costs and benefits.


BioPharm International
Volume 22, Issue 8

CONCLUSION

In conclusion, biopharmaceutical manufacturing's current proliferation of capacity and the trend toward an increasing number of small-volume products creates unique challenges in manufacturing economics studies. The high indirect costs of biopharmaceutical manufacturing means that any plant downtime for retrofitting raise the bar for performance improvement efforts to overcome. Typically, improvements with significant benefit to the organization focus on creating additional capacity (or additional effective capacity, such as reduced changeover times). In such analyses, however, producing accurate process models is of vital importance in establishing correct metrics around the economic benefits of any scenarios considered.

Rick Johnston is co-director at the Center for Biopharmaceutical Operations, University of California, Berkeley, and David Zhang is principal at Bioproduction Group, Inc. Berkeley, CA, 650.823.7533,

REFERENCES

1. The University of California at Berkeley. Center for Biopharmaceutical Operations; 2009. Available frome: http://cbo.berkeley.edu/.

2. Numbers indicative only.

3. Bioproduction Group. Indicative times only, not from any specific single biopharmaceutical manufacturer. Comparative durations for times retained, X and Y scales normalized. Processing step includes inline testing. Rejected batches removed.

4. Yang A. Genentech Simulation System. CBO Workshop; 21 May 2008. Available from: http://cbo.berkeley.edu/.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here